|

Axi-cel Clinical Trials

2 actively recruiting trials across 1 location

Also known as: Axicabtagene ciloleucel, KTE-C19, KTE-X19

Pipeline

Phase 2: 2

Top Sponsors

  • University Medical Center Groningen1
  • M.D. Anderson Cancer Center1

Indications

  • Cancer2
  • NHL1
  • DLBCL - Diffuse Large B Cell Lymphoma1
  • B Cell Lymphoma1

Other1 trial

Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL
Phase 2

Houston, Texas1 trial

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

MD Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.